Barclays Starts AnaptysBio (ANAB) at Overweight

October 13, 2025 3:08 AM UTC Send to a Friend
Barclays analyst Etzer Darout initiates coverage on AnaptysBio (NASDAQ: ANAB) with a Overweight rating and a price target of $78.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login